FDA Approves Rituxan Plus Chemotherapy for the Most Common Type of Adult Leukemia

Thursday, February 18, 2010 1 min read

Key Takeaway: FDA Approves Rituxan Plus Chemotherapy for the Most Common Type of Adult Leukemia

Full Press Release Details

FDA Approves Rituxan Plus Chemotherapy for the Most Common Type of Adult Leukemia.